555 results on '"Isidori, Alessandro"'
Search Results
2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
3. Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant
4. Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
5. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
6. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
7. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline
8. Iron toxicity – Its effect on the bone marrow
9. PB2379: SPECIFIC ALTERATIONS IN MEMBRANE LIPID LEVELS AS POTENTIAL BIOMARKERS IN DLBCL PATIENTS
10. P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
11. XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT
12. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
13. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib
14. Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study
15. Editorial: The management of hematologic malignancies in lower-income countries
16. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
17. Data from Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling
18. Supplementary Methods, Figures, and Tables from Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling
19. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
20. Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis
21. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
22. SARS-CoV-2 impact in a community-based hematological ward in an Italian Red Zone
23. Editorial: COVID-19 and hematological malignancies: Volume II
24. Treatment options for acute myeloid leukemia patients aged <60 years
25. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival
26. Stem Cell Mobilization: An Overview
27. Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
28. Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients
29. Editorial: Strengths and Challenges of Allo-SCT in the Modern Era
30. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients
31. Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma
32. The changing landscape for patients with relapsed/refractory acute myeloid leukaemia
33. Safety of FLT3 inhibitors in patients with acute myeloid leukemia
34. Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study
35. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment
36. Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study
37. Nanomedicine strategies for hematological malignancies: what is next?
38. Clinical Experience with Liposomal Doxorubicin
39. Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
40. Immunotherapy in Acute Myeloid Leukemia: Where We Stand
41. Current Challenges in Hematology: Awareness, Prevention, Equity
42. Editorial: The Biological Landscape of Immunotherapy in AML
43. Conditioning regimens in acute myeloid leukemia
44. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
45. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients
46. Positive Selection and Transplantation of Autologous Highly Purified CD133 + Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging
47. Second primary malignancy in myelofibrosis patients treated with ruxolitinib
48. Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
49. Anthracycline Cardiotoxicity
50. High-dose therapy followed by stem cell transplantation in Hodgkinʼs lymphoma: past and future
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.